9,10-dihydroxy-12-octadecenoic acid profile

9,10-dihydroxy-12-octadecenoic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

9,10-DiHOME : A DiHOME obtained by formal dihydroxylation of the 9,10-double bond of octadeca-9,12-dienoic acid (the 12Z-geoisomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5282958
CHEBI ID	190147
MeSH ID	M0307110

Synonym
(e)-9,10-dihydroxyoctadec-12-enoic acid
CHEBI:190147
(9xi,10xi,12xi)-9,10-dihydroxy-12-octadecenoic acid
9,10-dihydroxy-12-octadecenoic acid
9,10-dihome(12)
LMFA02000161
9,10-dihome
263399-34-4
Q50318264

Class	Description
long-chain fatty acid	A fatty acid with a chain length ranging from C13 to C22.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Linoleic acid oxylipin metabolism	0	13

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (11.11)	18.2507
2000's	4 (44.44)	29.6817
2010's	2 (22.22)	24.3611
2020's	2 (22.22)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (9.09%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (90.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
14,15-epoxy-5,8,11-eicosatrienoic acid 14,15-epoxy-5,8,11-eicosatrienoic acid: RN given refers to cpd without isomeric designation	2.06	1	long-chain fatty acid
9,10-epoxystearic acid 9,10-epoxystearic acid: RN given refers to parent cpd with unspecified isomeric designation; structure. 9,10-epoxyoctadecanoic acid : An epoxy fatty acid consisting of octadecanoic (stearic) acid with a single epoxide located between positions 9 and 10.	3.35	1	epoxystearic acid	human metabolite
chalcone trans-chalcone : The trans-isomer of chalcone.	2	1	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	3.83	3	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
8,11,14-eicosatrienoic acid 8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.	2.06	1	fatty acid 20:3; long-chain fatty acid	fungal metabolite; human metabolite; nutraceutical
9,10-epoxy-12-octadecenoate 9,10-epoxy-12-octadecenoic acid: toxic metabolite of leukocytes; causes cardiac failure in dogs; RN given refers to cpd without isomeric designation	2.06	1	medium-chain fatty acid
14,15-dihydroxyeicosatrienoic acid (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid : A DHET obtained by formal dihydroxylation across the 14,15-double bond of arachidonic acid.	2.06	1	DHET; diol; secondary allylic alcohol	mouse metabolite
leukotoxin leukotoxin: do not confuse with leukotoxin which is 9,10-epoxy-12-octadecenoate	4.4	6
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2	1

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	3.17	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.17	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.06	1
Arrhythmia [description not available]	2	1
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	2	1
Anasarca [description not available]	2	1
Acute Respiratory Distress Syndrome [description not available]	2	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2	1
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	2	1

9,10-dihydroxy-12-octadecenoic acid

Description

Cross-References

Synonyms (9)

Drug Classes (1)

Pathways (1)

Research

Studies (9)

Market Indicators

Research Demand Index: 12.47

Study Types